19 research outputs found
Modeling and Mechanistic Investigation of α-synuclein aggregation
Our understanding of the α-synuclein aggregation process and the consequences thereof is currently limited, which in turn prevents the development of targeted therapeutic interventions. The work presented here, as a part of this thesis, is focused on expanding our understanding of the molecular events involved in α-synuclein aggregation. Towards this goal we have studied the impact of pathologically relevant forms of α-synuclein, namely A53T mutant α-synuclein and fibrillar α-synuclein, and characterized their impact on N-methyl-D-aspartate receptor (NMDAR) diffusion and function. We found both mutant and fibrillar α-synuclein, decreased the NMDAR diffusion and expression at the post-synapse. Moving further towards the mechanistic investigations we investigated the effect of two neuroprotective compounds on α-synuclein aggregation and found both compounds capable of clearing α-synuclein in cell and animal models potentially through autophagy related functions. In our efforts to scale mechanistic investigations we developed a high-throughput screening (HTS) capable FRET-based reporter for detection of α-synuclein aggregation in cells. Using this model, we performed a proof-of-concept screen of kinase inhibitors from which we identified three inhibitors with potent protective effects on α-synuclein aggregation. We further showed through mechanistic investigation that the protective effects likely involved lysosomal changes. Finally, in an effort to advance our knowledge of α-synuclein aggregation, we performed a genome-wide knockout screen to identify genes in the human genome with an impact on α-synuclein aggregation. This study also highlighted among other pathways the importance of the endolysosomal system in relation to α-synuclein aggregation. Many questions remain in regard to the molecular mechanisms involved in α-synuclein aggregation, but we hope our insights and models presented here will assist in the elucidation of the underlying mechanisms of α-synuclein aggregation
Cellular and molecular mechanisms involved in the uptake and clearance of α-synuclein in differentiated SH-SY5Y cells in the presence or absence of α-synuclein specific antibodies
Kalorimetriske undersøgelser af binære blandinger af ortho-terphenyl & ortho-phenylphenol: Calorimetric Studies of Binary Mixtures of Ortho-terphenyl & Ortho-phenylphenol
Udvikling af fryseprotokol til selektion af transfekterede HEK293 celler med AFP som selektionsmarkør: Development of a freeze-thaw protocol for transfected HEK293 cells using AFP as a selection marker
Undersøgelse af inklusionskomplekser mellem glykokonjugerede galdesalte og γ-cyklodextrin og (2-hydroxypropyl)-γ-cyklodextrin ved brug af ITC og NMR: Study of inclusioncomplexes of glycoconjugated bile salts with γ-cyclodextrin and (2-hydroxypropyl)-γ-cyclodextrin using ITC and NMR
Brain region-specific microglial and astrocytic activation in response to systemic lipopolysaccharides exposure
Microglia cells are the macrophage population within the central nervous system, which acts as the first line of the immune defense. These cells present a high level of heterogeneity among different brain regions regarding morphology, cell density, transcriptomes, and expression of different inflammatory mediators. This region-specific heterogeneity may lead to different neuroinflammatory responses, influencing the regional involvement in several neurodegenerative diseases. In this study, we aimed to evaluate microglial response in 16 brain regions. We compared different aspects of the microglial response, such as the extension of their morphological changes, sensitivity, and ability to convert an acute inflammatory response to a chronic one. Then, we investigated the synaptic alterations followed by acute and chronic inflammation in substantia nigra. Moreover, we estimated the effect of partial ablation of fractalkine CX3C receptor 1 (CX3CR1) on microglial response. In the end, we briefly investigated astrocytic heterogeneity and activation. To evaluate microglial response in different brain regions and under the same stimulus, we induced a systemic inflammatory reaction through a single intraperitoneal (i.p.) injection of lipopolysaccharides (LPS). We performed our study using C57BL6 and CX3CR1+/GFP mice to investigate microglial response in different regions and the impact of CX3CR1 partial ablation. We conducted a topographic study quantifying microglia alterations in 16 brain regions through immunohistochemical examination and computational image analysis. Assessing Iba1-immunopositive profiles and the density of the microglia cells, we have observed significant differences in region-specific responses of microglia populations in all parameters considered. Our results underline the peculiar microglial inflammation in the substantia nigra pars reticulata (SNpr). Here and in concomitance with the acute inflammatory response, we observed a transient decrease of dopaminergic dendrites and an alteration of the striato-nigral projections. Additionally, we found a significant decrease in microglia response and the absence of chronic inflammation in CX3CR1+/GFP mice compared to the wild-type ones, suggesting the CX3C axis as a possible pharmacological target against neuroinflammation induced by an increase of systemic tumor necrosis factor-alpha (TNFα) or/and LPS. Finally, we investigated astrocytic heterogeneity in this model. We observed different distribution and morphology of GFAP-positive astrocytes, a heterogeneous response under inflammatory conditions, and a decrease in their activation in CX3CR1 partially ablated mice compared with C57BL6 mice. Altogether, our data confirm that microglia and astrocytes heterogeneity lead to a region-specific inflammatory response in presence of a systemic TNFα or/and LPS treatment
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Adeno Associated Virus (AAV)-mediated gene expression in the brain is widely applied in the preclinical setting to investigate the therapeutic potential of specific molecular targets, characterize various cellular functions, and model central nervous system (CNS) diseases. In therapeutic applications in the clinical setting, gene therapy offers several advantages over traditional pharmacological based therapies, including the ability to directly manipulate disease mechanisms, selectively target disease-afflicted regions, and achieve long-term therapeutic protein expression in the absence of repeated administration of pharmacological agents. Next to the gold-standard iodixanol-based AAV vector production, we recently published a protocol for AAV production based on chloroform-precipitation, which allows for fast in-house production of small quantities of AAV vector without the need for specialized equipment. To validate our recent protocol, we present here a direct side-by-side comparison between vectors produced with either method in a series of in vitro and in vivo assays with a focus on transgene expression, cell loss, and neuroinflammatory responses in the brain. We do not find differences in transduction efficiency nor in any other parameter in our in vivo and in vitro panel of assessment. These results suggest that our novel protocol enables most standardly equipped laboratories to produce small batches of high quality and high titer AAV vectors for their experimental needs
Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson’s Disease
The enteric nervous system (ENS) controls the function of the gastrointestinal tract and has been implicated in various diseases, including Parkinson’s disease (PD). PD is a neurodegenerative disease with Lewy bodies (LBs) and Lewy neurites (LNs) as the main pathological features. In addition to the typical motor symptoms in PD, attention has been drawn to non-motor symptoms, such as constipation, implying dysfunction of the ENS. In the present study, we characterized the age-dependent morphological alterations and aggregation of α-synuclein (α-syn), the primary protein component in LBs and LNs, in the ENS in an α-syn transgenic mouse model. We found that the expression and accumulation of α-syn increased gradually in neurons of Meissner’s and Auerbach’s plexuses of the gastrointestinal tract with age (from 1 week to 2 years). In addition, α-syn was increasingly phosphorylated at the serine 129 residue, reflecting pathological alterations of the protein over time. Furthermore, α-syn was present in different subtypes of neurons expressing vasoactive intestinal polypeptide, neuronal nitric oxide synthase, or calretinin. The results indicated that BAC-α-Syn-GFP transgenic mice provide a unique model in which to study the relationship between ENS and PD pathogenesis
Litiums langtidsvarende effekter på principale celler i det distale nefron: The long term effects of lithium on principal cells in the distal nephron
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Adeno Associated Virus (AAV)-mediated gene expression in the brain is widely applied in the preclinical setting to investigate the therapeutic potential of specific molecular targets, characterize various cellular functions, and model central nervous system (CNS) diseases. In therapeutic applications in the clinical setting, gene therapy offers several advantages over traditional pharmacological based therapies, including the ability to directly manipulate disease mechanisms, selectively target disease-afflicted regions, and achieve long-term therapeutic protein expression in the absence of repeated administration of pharmacological agents. Next to the gold-standard iodixanol-based AAV vector production, we recently published a protocol for AAV production based on chloroform-precipitation, which allows for fast in-house production of small quantities of AAV vector without the need for specialized equipment. To validate our recent protocol, we present here a direct side-by-side comparison between vectors produced with either method in a series of in vitro and in vivo assays with a focus on transgene expression, cell loss, and neuroinflammatory responses in the brain. We do not find differences in transduction efficiency nor in any other parameter in our in vivo and in vitro panel of assessment. These results suggest that our novel protocol enables most standardly equipped laboratories to produce small batches of high quality and high titer AAV vectors for their experimental needs